Targeting IL-23 and Th17-Cytokines in Inflammatory Bowel Diseases

By  

Current Pharmaceutical Design, Vol. 16, Iss. 33, 2010-11 ,pp. : 3656-3660

Bentham Science Publishers

Access to resources Recommend Favorite

Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways

By  

Current Pharmaceutical Biotechnology, Vol. 18, Iss. 12, 2018-03 ,pp. : 964-978

Bentham Science Publishers

Access to resources Recommend Favorite

Lactic Acid Bacteria with Concomitant IL-17, IL-23 and TNFα- Binding Ability for the Treatment of Inflammatory Bowel Disease

By  

Current Pharmaceutical Biotechnology, Vol. 18, Iss. 4, 2017-05 ,pp. : 318-326

Bentham Science Publishers

Access to resources Recommend Favorite

The cytokines (IFN-γ, IL-2, IL-4, IL-10, IL-17) and Treg cytokine (TGF-β1) levels in adults with immune thrombocytopenia

By  

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 69, Iss. 9, 2014-09 ,pp. : 694-697

Govi-Verlag

Access to resources Recommend Favorite

The IL23/Th17 Pathway as a Therapeutic Target in Chronic Inflammatory Diseases

By  

Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol. 11, Iss. 2, 2012-04 ,pp. : 159-168

Bentham Science Publishers

Access to resources Recommend Favorite